These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36072763)

  • 1. Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.
    Grega SD; Zheng DX; Zheng QH
    Am J Nucl Med Mol Imaging; 2022; 12(4):113-121. PubMed ID: 36072763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
    Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
    Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of a Glypican-3-specific binding peptide using
    Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
    Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
    An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
    Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
    Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma.
    Nakatsura T; Nishimura Y
    BioDrugs; 2005; 19(2):71-7. PubMed ID: 15807627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPC-3 in hepatocellular carcinoma: current perspectives.
    Wu Y; Liu H; Ding H
    J Hepatocell Carcinoma; 2016; 3():63-67. PubMed ID: 27878117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
    Shih TC; Wang L; Wang HC; Wan YY
    Liver Res; 2020 Dec; 4(4):168-172. PubMed ID: 33384879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
    Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
    J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
    Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
    ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Guo Z; Wang J; Li L; Liu R; Fang J; Tie B
    World J Clin Cases; 2020 Aug; 8(16):3493-3502. PubMed ID: 32913856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma.
    Dickerson LK; Lehnert AL; Hamlin DK; Labadie KP; Goodsell KE; Liu Y; Li Y; Wilbur DS; Miyaoka R; Park JO
    Res Sq; 2024 Jun; ():. PubMed ID: 38978570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.